EP2595993A4 - COMPOUNDS ENHANCING TRICYCLIC PROTEIN ACTIVITY - Google Patents

COMPOUNDS ENHANCING TRICYCLIC PROTEIN ACTIVITY

Info

Publication number
EP2595993A4
EP2595993A4 EP11810459.5A EP11810459A EP2595993A4 EP 2595993 A4 EP2595993 A4 EP 2595993A4 EP 11810459 A EP11810459 A EP 11810459A EP 2595993 A4 EP2595993 A4 EP 2595993A4
Authority
EP
European Patent Office
Prior art keywords
protein activity
compounds enhancing
tricyclic
tricyclic protein
enhancing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP11810459.5A
Other languages
German (de)
French (fr)
Other versions
EP2595993A2 (en
EP2595993B1 (en
Inventor
Daniel Finley
Randall W King
Byung-Hoon Lee
Min Jae Lee
Timothy C Gahman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Publication of EP2595993A2 publication Critical patent/EP2595993A2/en
Publication of EP2595993A4 publication Critical patent/EP2595993A4/en
Application granted granted Critical
Publication of EP2595993B1 publication Critical patent/EP2595993B1/en
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
EP11810459.5A 2010-07-23 2011-07-22 Tricyclic proteasome activity enhancing compounds Not-in-force EP2595993B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36717310P 2010-07-23 2010-07-23
PCT/US2011/044999 WO2012012712A2 (en) 2010-07-23 2011-07-22 Tricyclic proteasome activity enhancing compounds

Publications (3)

Publication Number Publication Date
EP2595993A2 EP2595993A2 (en) 2013-05-29
EP2595993A4 true EP2595993A4 (en) 2014-01-08
EP2595993B1 EP2595993B1 (en) 2018-04-18

Family

ID=45497483

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11810459.5A Not-in-force EP2595993B1 (en) 2010-07-23 2011-07-22 Tricyclic proteasome activity enhancing compounds

Country Status (7)

Country Link
US (3) US8933087B2 (en)
EP (1) EP2595993B1 (en)
JP (1) JP6042331B2 (en)
CN (1) CN103119047B (en)
AU (1) AU2011281015B2 (en)
CA (1) CA2808432C (en)
WO (1) WO2012012712A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102844313B (en) * 2010-01-28 2016-10-05 哈佛大学校长及研究员协会 Compositions and methods for increasing proteasome activity
WO2012012712A2 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Tricyclic proteasome activity enhancing compounds
EP2663312B1 (en) 2011-01-10 2017-10-11 Nimbus Iris, Inc. Irak inhibitors and uses thereof
US9556166B2 (en) 2011-05-12 2017-01-31 Proteostasis Therapeutics, Inc. Proteostasis regulators
CN104582705A (en) 2012-01-10 2015-04-29 林伯士艾瑞斯公司 IRAK inhibitors and uses thereof
WO2013112651A2 (en) 2012-01-25 2013-08-01 Proteostasis Therapeutics, Inc. Proteasome activity modulating compounds
CN104902959A (en) 2012-07-11 2015-09-09 林伯士艾瑞斯公司 Irak inhibitors and uses thereof
EP2872144A4 (en) * 2012-07-11 2015-12-02 Nimbus Iris Inc IRAQ INHIBITORS AND USES THEREOF
JP2016504365A (en) 2012-12-28 2016-02-12 アメリカ合衆国 USP1 / UAF1 deubiquitinase complex inhibitor and use thereof
AU2014205577A1 (en) 2013-01-10 2015-05-28 Nimbus Iris, Inc. IRAK inhibitors and uses thereof
WO2014116228A1 (en) 2013-01-25 2014-07-31 President And Fellows Of Harvard College Usp14 inhibitors for treating or preventing viral infections
WO2014145576A2 (en) 2013-03-15 2014-09-18 Northwestern University Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer
EP3049086A4 (en) 2013-09-27 2017-02-22 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002088138A1 (en) * 2001-04-30 2002-11-07 Bayer Corporation Novel 4-amino-5,6-substituted thiopheno[2,3-d]pyrimidines

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3577420A (en) * 1968-01-05 1971-05-04 Pfizer Certain 4-aminofuro(2,3-d)pyrimidines
GB1570494A (en) * 1975-11-28 1980-07-02 Ici Ltd Thienopyrimidine derivatives and their use as pesticides
DD245666A1 (en) 1985-09-20 1987-05-13 Univ Halle Wittenberg PROCESS FOR PREPARING 4-AMINO-SUBSTITUTED THIENO 2,3-D-PYRIMIDIN-2-YLESSED ACID ESTERS
JPH01313480A (en) 1988-06-14 1989-12-18 Nippon Soda Co Ltd Pyrimidine derivative, its production and fungicide for agricultural and horicultural use
AU7890598A (en) * 1996-12-27 1998-07-31 Yoshitomi Pharmaceutical Industries, Ltd. Fused pyrimidine compounds and medicinal use thereof
KR20010105399A (en) 1999-03-30 2001-11-28 쓰끼하시 다미까따 Thienopyrimidine compounds and salts thereof and process for the preparation of the same
EP1175421A1 (en) 1999-04-30 2002-01-30 Neurogen Corporation 9H-PYRIMIDO[4,5-b]INDOLE DERIVATIVES: CRF1 SPECIFIC LIGANDS
JP2002105082A (en) 2000-09-29 2002-04-10 Nippon Soda Co Ltd Condensed thienopyrimidine compound, its salt and method of preparing the same
DE10064994A1 (en) 2000-12-23 2002-07-04 Merck Patent Gmbh Sulfamidothienopyrimidine
JP2004517940A (en) 2001-01-31 2004-06-17 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング Pharmaceutical formulations containing pyrazolo [4,3-d] pyrimidine and nitrate or thienopyrimidine and nitrate
DE10148883A1 (en) 2001-10-04 2003-04-10 Merck Patent Gmbh New fused bi- or tricyclic pyrimidine derivatives, are phosphodiesterase V inhibitors useful e.g. for treating impotence, cardiovascular disorders, inflammation or tumors
WO2003037898A1 (en) * 2001-10-31 2003-05-08 Bayer Healthcare Ag Pyrimido [4,5-b] indole derivatives
JP2003137886A (en) * 2001-10-31 2003-05-14 Bayer Ag PYRIMIDO[4,5-b]INDOLE
US7199119B2 (en) 2002-10-31 2007-04-03 Amgen Inc. Antiinflammation agents
ES2217956B1 (en) 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. NEW DERIVATIVES OF 4-AMINOTIENE (2,3-D) PIRIMIDIN-6-CARBONITRILE.
JP4677518B2 (en) * 2003-03-31 2011-04-27 エピックス デラウェア， インコーポレイテッド Novel piperidinylamino-thieno [2,3-D] pyrimidine compounds
US7612078B2 (en) * 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
JP5249772B2 (en) * 2005-11-22 2013-07-31 メルク・シャープ・アンド・ドーム・コーポレーション Tricyclic compounds useful as inhibitors of kinases
US7960400B2 (en) 2007-08-27 2011-06-14 Duquesne University Of The Holy Ghost Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof
US7982035B2 (en) 2007-08-27 2011-07-19 Duquesne University Of The Holy Spirit Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof
WO2009033581A1 (en) 2007-09-14 2009-03-19 Bayer Schering Pharma Aktiengesellschaft Substituted tricyclic compounds and methods of use thereof
US20100227853A1 (en) 2008-04-18 2010-09-09 Trustees Of Boston College Inhibitors of cyclic amp phosphodiesterases
US8507502B2 (en) 2008-11-10 2013-08-13 National Health Research Institutes Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors
KR20110136819A (en) 2009-02-27 2011-12-21 시가 테크놀로지스, 인크. Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infection
CN102844313B (en) 2010-01-28 2016-10-05 哈佛大学校长及研究员协会 Compositions and methods for increasing proteasome activity
WO2012012712A2 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Tricyclic proteasome activity enhancing compounds
TW201219401A (en) 2010-09-14 2012-05-16 Lexicon Pharmaceuticals Inc Bicyclic inhibitors of Notum Pectinacetylesterase and methods of their use
CN103261205B (en) 2010-11-12 2015-08-19 姚雪彪 Dynamic some motor protein CENP-E micromolecular inhibitor SYNTELIN and application thereof
EP2663312B1 (en) 2011-01-10 2017-10-11 Nimbus Iris, Inc. Irak inhibitors and uses thereof
CN104582705A (en) 2012-01-10 2015-04-29 林伯士艾瑞斯公司 IRAK inhibitors and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002088138A1 (en) * 2001-04-30 2002-11-07 Bayer Corporation Novel 4-amino-5,6-substituted thiopheno[2,3-d]pyrimidines

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
D. BRIEL ET AL: "Thieno[2,3-d]pyrimidine als Glutamatantagonisten", DIE PHARMAZIE, vol. 63, no. 11, 1 November 2008 (2008-11-01), pages 823 - 826, XP055089149, ISSN: 0031-7144, DOI: 10.1691/ph.2008.8600 *
PEDEBOSCQ S ET AL: "Synthesis and study of antiproliferative activity of novel thienopyrimidines on glioblastoma cells", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 45, no. 6, 1 June 2010 (2010-06-01), pages 2473 - 2479, XP027013917, ISSN: 0223-5234, [retrieved on 20100218] *
See also references of WO2012012712A2 *

Also Published As

Publication number Publication date
US20160039839A1 (en) 2016-02-11
CN103119047A (en) 2013-05-22
CN103119047B (en) 2016-06-15
WO2012012712A3 (en) 2012-05-31
US20130210845A1 (en) 2013-08-15
AU2011281015A1 (en) 2013-03-07
JP6042331B2 (en) 2016-12-14
EP2595993A2 (en) 2013-05-29
US8933087B2 (en) 2015-01-13
CA2808432C (en) 2019-06-04
AU2011281015B2 (en) 2015-09-24
CA2808432A1 (en) 2012-01-26
EP2595993B1 (en) 2018-04-18
WO2012012712A2 (en) 2012-01-26
US20180265519A1 (en) 2018-09-20
US9981981B2 (en) 2018-05-29
JP2013532662A (en) 2013-08-19

Similar Documents

Publication Publication Date Title
EP2595993A4 (en) COMPOUNDS ENHANCING TRICYCLIC PROTEIN ACTIVITY
EP2774928A4 (en) POLYCYCLIC PYRIDONE DERIVATIVE HAVING INEGRASE-INHIBITING ACTIVITY
SMT201500054B (en) 2-Anilinobenzimidazole-6-carboxamides as agent-inflammatory agents
EP2590647A4 (en) PRONEUROGENIC COMPOUNDS
EP2773334A4 (en) COMPOSITION HAVING ANTIMICROBIAL ACTIVITY EXTENDED
EP2491025A4 (en) AZA-AZULENE COMPOUNDS
EP2723741A4 (en) SUBSTITUTED IMIDAZOPYRIDINYL AMINOPYRIDINE COMPOUNDS
EP2673286A4 (en) THERAPEUTIC COMPOUNDS
EP2648516A4 (en) SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS
EP2320907A4 (en) THERAPEUTIC COMPOUNDS
EP2903617A4 (en) INHIBITORS OF IRAQ4 ACTIVITY
IL225245A0 (en) Gel compound
EP2640853A4 (en) MODULATION OF THE EXPRESSION OF ALPHA SYNUCLEIN
EP2605658A4 (en) SPIROXAZOLIDINONE COMPOUNDS
IT1399597B1 (en) "DISPOSABLE SHAKER"
EP2268285A4 (en) THERAPEUTIC COMPOUNDS
BRPI1007878A2 (en) "insecticidal compounds"
DK2598514T3 (en) Protein purification
HRP20150167T1 (en) COMPOUNDS AS BRADIKININ-B1 ANTAGONISTS
EP2806876A4 (en) COMPOUNDS ENHANCING THE ACTIVITY OF PROTEASOMES
EP2616453A4 (en) ANTIMETASTATIC COMPOUNDS
EP2555766A4 (en) ANTIMETASTATIC COMPOUNDS
BR302012001179S1 (en) "Beacon Applied Configuration"
EP2909321A4 (en) STABLE NON-POLYADENYLNA RNA PRODUCTION
EP2546231A4 (en) ALKYLAMINE DERIVATIVE

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130212

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20131205

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 495/04 20060101AFI20131129BHEP

Ipc: A61K 31/519 20060101ALI20131129BHEP

Ipc: A61P 25/28 20060101ALI20131129BHEP

Ipc: C07D 487/04 20060101ALI20131129BHEP

17Q First examination report despatched

Effective date: 20150504

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20171117

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 990334

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180515

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602011047637

Country of ref document: DE

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 8

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20180418

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180718

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180718

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180719

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 990334

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180418

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180820

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602011047637

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

26N No opposition filed

Effective date: 20190121

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180722

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20180731

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180722

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180731

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180731

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20190726

Year of fee payment: 9

Ref country code: DE

Payment date: 20190729

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20190729

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180722

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20110722

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180418

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180818

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602011047637

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20200722

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200722

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210202